• Baked In
  • Posts
  • 🌿 Insanity Is Doing The Same Thing Over and Over Again and Expecting Different Results

🌿 Insanity Is Doing The Same Thing Over and Over Again and Expecting Different Results

GM Everyone,

Fun Fact: 8 in 10 marijuana consumers use the plant as a substitute for prescription drugs.

How about them apples.

💸 The Tape

Florida’s latest shot at legalizing marijuana is rolling forward with noticeable momentum. The Smart & Safe Florida campaign has now gathered more than 613,000 valid signatures—about 70 percent of what’s needed to put adult-use cannabis back on the ballot in 2026. The magic number? 880,062 valid signatures, plus geographic distribution across at least 14 of Florida’s 28 congressional districts.

This marks the second attempt by the campaign after falling short at the finish line in 2024. Despite landing on the ballot and even receiving an endorsement from Donald Trump, the initiative failed to hit Florida’s notoriously tough 60 percent supermajority threshold required for constitutional amendments.

So what’s different this time?

For starters, the campaign has added clearer language to address criticisms from the opposition. Public consumption is now explicitly banned in the amendment, and the legislature is given rulemaking authority over when and where marijuana can be consumed. The goal? Tighten up the initiative to make it more court-proof and voter-friendly.

Speaking of courts, Gov. Ron DeSantis (R) isn’t shy about his skepticism. He recently declared the initiative is in “big time trouble” with the Florida Supreme Court, suggesting it’s too broad and inappropriate for the state constitution. Ironically, DeSantis accurately predicted that the 2024 version would survive the legal gauntlet—so perhaps his pessimism this time is political posturing… or maybe he's just hedging his bets.

Despite the governor’s disapproval and new legislation that tightens ballot initiative rules, Smart & Safe Florida is pushing ahead with deep-pocketed support—Trulieve, Florida’s dominant cannabis operator, bankrolled much of the previous effort and appears to be back in the mix.

Public sentiment still leans green. A February poll showed 67% of Floridians support legalization—including a majority of Republicans. But the Florida Chamber of Commerce, a reliable voice of “No,” released a dueling poll showing support at 53%—short of the threshold.

So far, the campaign has only hit the signature threshold in three congressional districts, but it’s closing in on the required spread. If it stays on pace, voters could have a rematch with cannabis reform in November 2026.

For now, the race is on: between signature collectors, state lawmakers, and the ever-watchful eyes of the courts. In Florida, it’s not just about winning public support—it’s about navigating a legal minefield to get that question on the ballot in the first place.

📈 Dog Walkers.

$ROMJ.TSX ( 0.0% ) Rubicon Goes Full Spectrum

What’s Going On Here: Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF), a Canadian leader in premium organic cannabis, has announced the launch of its new 1964 Supply Co.™ All-in-One (AIO) Full Spectrum Extract (FSE) Resin Vapes. Following the strong reception of its 510 FSE cartridges in May 2024, this AIO format offers enhanced convenience and showcases Rubicon’s signature terpene-rich extracts.

The first release features the popular “Comatose” strain in a 0.5g format, debuting in British Columbia and expanding nationwide (excluding Quebec) throughout 2025. Two additional AIO SKUs are slated for release by year-end.

“This launch is a strategic milestone in Rubicon’s growth,” said CEO Margaret Brodie. “We’re delivering premium full-spectrum vapes at an accessible price point.”

Notably, 1964’s AIO vape is one of the only FSE resin-based options in a segment largely dominated by distillate products—positioning it to attract both legacy consumers and modern connoisseurs seeking authentic flavor and quality.

$CRON ( ▲ 4.17% ) Cronos Expands In The EU

What’s Going On Here: Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has announced the expansion of its PEACE NATURALS® medical cannabis brand into the Swiss market through a new partnership with Dascoli Pharma AG, a Swiss-based distributor specializing in medical cannabis and healthcare training.

“This collaboration supports our goal of providing borderless cannabis access across Europe,” said Mike Gorenstein, Cronos’ Chairman, President, and CEO. “With Dascoli’s strong local network, we can better serve Swiss patients with consistent, high-quality products.”

Under the agreement, Cronos will supply PEACE NATURALSÂŽ cannabis flower for distribution across Switzerland, including strains like GMO Cookies, Space Cake, Atomic Sour Grapefruit, Sonic Lemon Fuel, and Wedding Cake.

This move further advances Cronos’ international growth strategy. PEACE NATURALS® is now available in Australia, Canada, Germany, Israel, Malta, Switzerland, and the UK, reinforcing the brand’s global medical footprint.

🗞️ The News

📺 YouTube

NLCP CEO on SAFE Banking + atai Life Sciences $50m Raise Explained | TTB Powered By Dutchie

What we will cover:

✅ Host Shadd Dales and co-host Anthony Varrell welcome Anthony Coniglio, CEO of NewLake Capital Partners (OTCQX: NLCP), to respond to one of the most provocative interviews we’ve aired to date — featuring former hedge fund manager and institutional investor Marc Cohodes.

Earlier this week, Cohodes delivered an unfiltered, high-conviction case for why federal cannabis reform is coming — and fast. He made bold claims: the U.S. government is finally serious about cracking down on the illicit market, and the DEA, DHS, and Treasury are laying the groundwork for cannabis policy shifts that could include safe banking, rescheduling, and even nationwide taxation under a second Trump administration.

But is it all hype? Or is there real momentum building?

As the head of a major U.S. cannabis REIT, Anthony Coniglio offers a grounded, data-backed view of the situation. In this episode, he reacts to Cohodes’ commentary on: • The growing enforcement pressure on illegal grows • The merging narrative around hemp and cannabis as one regulated product • Whether the illicit-to-legal transition is finally happening • The need for U.S. cannabis companies to trade on U.S. exchanges • And what federal policy reform could mean for investors, operators, and capital markets.